RE:Recent Posts
CADInvestor12 wrote: I would read this board to try and get other investors opinions on earnings/ developments etc. Some have interesting perspectives, while others are completely clueless. I'm surprised with the recent opinions, frankly it proves that most of you have no idea what you're talking about. Yes, the share price is frustrating and the longer term growth catalysts are taking longer than expected but how can you not be impressed with the current exec team? The business has completely turned around, when Pidduck started TTM revenue was ~$21.1M & losing ~$48M (Q1/22 to Q2/21). Now TTM revenue is ~$37M & losing ~$13M and we're on the cusp of positive EBITDA + cash flow. Over the last 2 years revenue has almost doubled, while savings of ~$35M have been realized. With Medipharms existing infrastructure any M&A deal (even if they use equity) would be accretive and would create more value/ a better use of cash than a share buyback. For those spewing garbage about managements poor performance & advocating buybacks, give your head a shake and go invest in mutual funds. You don't belong here and have no idea what it takes to successfully grow/ turn a business around.
agreed fully that existing executive management deserves kudos and not ire for turning this business around. Where I disagree is that any form of M&A is beneficial and that a buyback would be less so. Do honestly think that this business, even with its growth trajectory, could withstand the weight of further dilution in the short the medium term?
I don't mind sensible M&A but I've been around for a while now and the time is now to start giving back to long term shareholders. A buyback would do so IMO.